Mostrando 4 resultados de: 4
Filtros aplicados
Subtipo de publicación
Article(4)
Publisher
Clinical Cancer Research(1)
Endocrinology(1)
European Journal of Endocrinology(1)
Journal of Steroid Biochemistry and Molecular Biology(1)
Origen
scopus(4)
3β-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer
ArticleAbstract: Prostate cancer usually responds to androgen deprivation therapy, although the response in metastatiPalabras claves:Autores:Evaul K., Li R., Papari-Zareei M., Richard J. Auchus, Sharifi N.Fuentes:scopusDevelopment and validation of a novel LC–MS/MS method for simultaneous determination of abiraterone and its seven steroidal metabolites in human serum: Innovation in separation of diastereoisomers without use of a chiral column
ArticleAbstract: Abiraterone acetate (AA), the prodrug of abiraterone, is FDA-approved for the treatment of castratioPalabras claves:abiraterone, LC–MS/MS, Metabolites, Method validation, Prostate cancerAutores:Alyamani M., Anderson D., Li Z., Richard J. Auchus, Sharifi N., Upadhyay S.K.Fuentes:scopusAbiraterone acetate treatment lowers 11-oxygenated androgens
ArticleAbstract: Context: The human adrenal is the dominant source of androgens in castration-resistant prostate cancPalabras claves:Autores:Alyamani M., O'Day P.J., Richard J. Auchus, Sharifi N., Wright C.Fuentes:scopusAbiraterone inhibits 3β-hydroxysteroid dehydrogenase: A rationale for increasing drug exposure in castration-resistant prostate cancer
ArticleAbstract: Purpose: Treatment with abiraterone (abi) acetate prolongs survival in castration-resistant prostatePalabras claves:Autores:Chang K.H., Evaul K., Li R., Liu J., Richard J. Auchus, Sharifi N., Sharma K.K., Yoshimoto J.A.Fuentes:scopus